The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Predictors of HIV Drug‐Resistance Mutations in a Large Antiretroviral‐Naive Cohort Initiating Triple Antiretroviral Therapy
Open accessAbstract
OBJECTIVE: The objective of this study was to systematically characterize the incidence and determinants of antiretroviral resistance in the HOMER (Highly Active Antiretroviral Therapy [HAART] Observational Medical Evaluation and Research) cohort of 1191 human immunodeficiency virus-infected, antiretroviral-naive adults initiating HAART in British Columbia, Canada. METHODS: All plasma samples with plasma virus loads (pVLs) >1000 copies/mL collected during the first 30 months of follow-up were genotyped for drug resistance. The primary outcome measure was time to the first detection of major drug-resistance mutation(s). Cox proportional hazard regression was used to identify factors significantly associated with the detection of drug-resistance mutations. RESULTS: Drug-resistance mutations were detected in 298 subjects (25%). Factors significantly associated with detection of drug-resistance mutations included high baseline pVL (multivariate hazard ratio [HR], 1.59; P<.001) and adherence (estimated using prescription-refill data and/or untimed plasma drug-concentration measurements). When compared with subjects with low (0%-<20%) prescription-refill percentages, subjects at an elevated risk of harboring drug-resistance mutations were those with relatively high but imperfect prescription-refill percentages (80%-<90%; multivariate HR, 4.15; P<.001) and those with essentially perfect (>/=95%) refill percentages but with 2 plasma drug concentrations below the steady-state trough concentration minus 1 standard deviation (multivariate HR, 4.57; P<.001). Initial use of nonnucleoside reverse-transcriptase inhibitor-based HAART was significantly associated with multiclass drug resistance (multivariate HR, 1.84; P=.001). CONCLUSION: High baseline pVLs and substantial but imperfect levels of adherence were major predictors of antiretroviral resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., & Holmberg, S. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381301 · Cited by 9,405
Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection
Paterson, D. L., Swindells, S., Mohr, J., Brester, M., Vergis, E. N., Squier, C., Wagener, M. M., & Singh, N. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-1-200007040-00004 · Cited by 3,289
Egger, M., May, M., Chêne, G., Phillips, A. N., Ledergerber, B., Dabis, F., Costagliola, D., Monforte, A. D., de Wolf, F., Reiss, P., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09411-4 · Cited by 1,525
Self-citationNon-adherence to highly active antiretroviral therapy predicts progression to AIDS
Bangsberg, D. R., Perry, S., Charlebois, E. D., Clark, R. A., Roberston, M., Zolopa, A. R., & Moss, A. (2001) · AIDS · doi:10.1097/00002030-200106150-00015 · Cited by 960
Ledergerber, B., Egger, M., Opravil, M., Telenti, A., Hirschel, B., Battegay, M., Vernazza, P., Sudre, P., Flepp, M., Furrer, H., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)01122-8 · Cited by 906
Hirsch, M. S., Brun-Vézinet, F., D'Aquila, R. T., Hammer, S. M., Johnson, V. A., Kuritzkes, D. R., Loveday, C., Mellors, J. W., Clotet, B., Conway, B., et al. (2000) · JAMA · doi:10.1001/jama.283.18.2417 · Cited by 766
Hogg, R. S. (2001) · JAMA · doi:10.1001/jama.286.20.2568 · Cited by 728
Self-citationHirsch, M. S., Günthard, H. F., Schapiro, J. M., Brun‐Vézinet, F., Clotet, B., Hammer, S. M., Johnson, V. A., Kuritzkes, D. R., Mellors, J. W., Pillay, D., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/589297 · Cited by 573
Schuurman, R., Nijhuis, M., van Leeuwen, R., Schipper, P., de Jong, D., Collis, P., Danner, S. A., Mulder, J., Loveday, C., Christopherson, C., et al. (1995) · Journal of Infectious Diseases · doi:10.1093/infdis/171.6.1411 · Cited by 503
Correction: Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection
(2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-3-200202050-00020 · Cited by 502
Cited by
Gazzard, B., & on behalf of the BHIVA Treatment Guidelines Writing Group (2008) · HIV Medicine · doi:10.1111/j.1468-1293.2008.00636.x · Cited by 1,089
Thompson, M. A., Mugavero, M. J., Amico, K. R., Cargill, V. A., Chang, L. W., Gross, R., Orrell, C., Altice, F. L., Bangsberg, D. R., Bartlett, J. G., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-11-201206050-00419 · Cited by 582
Bangsberg, D. R. (2006) · Clinical Infectious Diseases · doi:10.1086/507526 · Cited by 534
Shubber, Z., Mills, E. J., Nachega, J. B., Vreeman, R., Freitas, M., Bock, P., Nsanzimana, S., Penazzato, M., Appolo, T., Doherty, M., et al. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1002183 · Cited by 526
Nachega, J. B., Hislop, M., Nguyen, H., Dowdy, D. W., Chaisson, R. E., Regensberg, L., Cotton, M., & Maartens, G. (2009) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e318199072e · Cited by 449
Adherence to Nonnucleoside Reverse Transcriptase Inhibitor–Based HIV Therapy and Virologic Outcomes
Nachega, J. B., Hislop, M., Dowdy, D. W., Chaisson, R. E., Regensberg, L., & Maartens, G. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-8-200704170-00007 · Cited by 374
Social Stigma Concerns and HIV Medication Adherence
Rintamaki, L. S., Davis, T. C., Skripkauskas, S., Bennett, C. L., & Wolf, M. S. (2006) · AIDS Patient Care and STDs · doi:10.1089/apc.2006.20.359 · Cited by 370
Feng, X., Xu, W., Li, Z., Song, W., Ding, J., & Chen, X. (2019) · Advanced Science · doi:10.1002/advs.201900101 · Cited by 363
Sweeney, S. M., & Vanable, P. A. (2016) · AIDS and Behavior · doi:10.1007/s10461-015-1164-1 · Cited by 350
Sevelius, J. M., Patouhas, E., Keatley, J. G., & Johnson, M. O. (2014) · Annals of Behavioral Medicine · doi:10.1007/s12160-013-9565-8 · Cited by 345
Bibliometric analysis of worldwide scientific literature in mobile - health: 2006–2016
Sweileh, W. M., Al-Jabi, S. W., AbuTaha, A. S., Zyoud, S. H., Anayah, F. M. A., & Sawalha, A. F. (2017) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-017-0476-7 · Cited by 319
Bangsberg, D. R., Acosta, E. P., Gupta, R., Guzman, D., Riley, E. D., Harrigan, P. R., Parkin, N., & Deeks, S. G. (2006) · AIDS · doi:10.1097/01.aids.0000199825.34241.49 · Cited by 312
Self-citationAdherence to Highly Active Antiretroviral Therapy (HAART): A Meta-Analysis
Ortego, C., Huedo-Medina, T. B., Llorca, J., Sevilla, L., Santos, P., Rodríguez, E., Warren, M. R., & Vejo, J. (2011) · AIDS and Behavior · doi:10.1007/s10461-011-9942-x · Cited by 310
HIV Treatment Adherence, Drug Resistance, Virologic Failure: Evolving Concepts
B. Nachega, J., C. Marconi, V., U. van Zyl, G., M. Gardner, E., Preiser, W., Y. Hong, S., J. Mills, E., & Gross, R. (2011) · Infectious Disorders - Drug Targets · doi:10.2174/187152611795589663 · Cited by 271
Hermisson, J., & Pennings, P. S. (2017) · Methods in Ecology and Evolution · doi:10.1111/2041-210x.12808 · Cited by 257
Emerging Nanotechnology Approaches for HIV/AIDS Treatment and Prevention
Mamo, T., Moseman, E. A., Kolishetti, N., Salvador-Morales, C., Shi, J., Kuritzkes, D. R., Langer, R., Andrian, U. V., & Farokhzad, O. C. (2010) · Nanomedicine · doi:10.2217/nnm.10.1 · Cited by 255
Gupta, R. K., Hill, A., Sawyer, A. W., Cozzi-Lepri, A., von Wyl, V., Yerly, S., Lima, V. D., Günthard, H. F., Gilks, C., & Pillay, D. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70136-7 · Cited by 254
Preventing HIV Antiretroviral Resistance through Better Monitoring of Treatment Adherence
Bangsberg, D. R. (2008) · The Journal of Infectious Diseases · doi:10.1086/533415 · Cited by 183
Mimtsoudis, I., Tsachouridou, O., Akinosoglou, K., & Metallidis, S. (2024) · Viruses · doi:10.3390/v16091392 · Cited by 13
Pfeiffer, J. T., Napúa, M., Wagenaar, B. H., Chale, F., Hoek, R., Micek, M., Manuel, J., Michel, C., Cowan, J. G., Cowan, J. F., et al. (2017) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001515 · Cited by 12
Metadata
- Authors
- Harrigan, P. R., Hogg, R. S., Dong, W. W. Y., Yip, B., Wynhoven, B., Woodward, J., Brumme, C. J., Brumme, Z. L., Mo, T., Alexander, C. S., & Montaner, J. S. G.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-02
- Volume
- 191
- Issue
- 3
- Pages
- 339-347
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2047734031
- Cited by
- 424
- References
- 28
- FWCI
- 18.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.